Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech

Why did Nvidia stock slip amid tariffs? What drives Microsoft's new Copilot AI agents? How are tariffs impacting U.S. stock markets? What boosted HDI Global's insurance revenue? Why is the EU probing Huawei corruption? How are trade wars sapping market liquidity? Why did American Express stock drop sharply? What does 23andMe bankruptcy mean for data? What triggered Rolls-Royce share price surge?

Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech

benzinga.com/general/biotech/25/03/44459637/novo-nordisk-to-pay-around-2-billion-for-obesity-drug-from-china-based-biotech

On Monday, The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) entered into an exclusive license agreement for an obesity drug.
Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong…

This story appeared on benzinga.com, 2025-03-24 14:42:36.